Update of international guidelines for cervical cancer screening

R.E. Bohîlțea, C. Grigoriu, C.M. Gheorghe, I. Ducu, B. Mihai, M. Mitran, C. Berceanu, R. Vlădăreanu

Rezumat: Cervical cancer mainly affects women in developing countries, its incidence and mortality rates being closely related to the availability of programs of screening and vaccination against human papillomavirus (HPV). By 2020, the World Health Organization Global Strategy to eliminate the threshold of four cases of cervical cancer per 100,000 women per year by the end of the century implies achieving the following goals by 2030 and maintaining them: 90% of girls should be fully vaccinated for HPV by the age of 15; 70% of women should be screened by a high-performance test until the age of 35 and then again until the age of 45, so that each woman is tested at least twice in her lifetime, at a distance of maximum 10 years between tests; 90% of women identified with cervical pathology should receive treatment. In this article, we review the recommendations of the USA specialty societies regarding the cervical cancer screening in women with baseline risk, of the European guidelines on providing a quality screening for cervical cancer, and of the Australian guide.
Cuvinte cheie: cervical cancer, human papillomavirus (HPV), oncogenic strains, HPV testing.